Recovery for Patients, Families and Communities

www.aatod.org
Dear Colleagues, Patients, Advocates, Stakeholders and Friends:

On behalf of the American Association for the Treatment of Opioid Dependence, Inc. (AATOD), and our host the State of Nevada Department of Health and Human Services/Division of Mental Health and Developmental Services/Substance Abuse Prevention and Treatment Agency, it is my pleasure to invite you to the 2012 AATOD National Conference. The conference will convene April 21-25, 2012 at the Venetian | Palazzo in beautiful Las Vegas.

AATOD has a history of providing an outstanding conference experience jam-packed with opportunities that will help treatment providers deliver quality care with dignity and respect to patients; while providing a forum for discussion and debate on the challenges that face the treatment field. Our planning committees have worked diligently to ensure a diverse and fascinating program.

This year’s theme is “Recovery for Patients, Families and Communities” and is woven throughout the Plenary Sessions, Workshops, Posters, Hot Topic Roundtables, and other conference activities.

The AATOD Conference is the largest gathering of the opioid treatment community. You will have unparalleled opportunities to meet with and learn from colleagues from the nation and many other countries. Much of the benefit of the conference comes from the informal interactions. This conference is attended by representatives from federal and state government entities, provider organizations, researchers, clinicians, patient advocates, administrators, and accrediting bodies. There are chances to make direct contact with national and local AATOD representatives, federal and state officials, and other delegates during various activities such as: the Open AATOD Board Meeting, Welcome Reception, Continental Breakfasts, Refreshment Breaks, memorable Awards Banquet and other conference activities. The exhibits provide possibilities to examine new technologies, and learn about new and innovative options for your programs while getting acquainted with potential vendors.

Las Vegas is known for its excitement and natural beauty. It is no surprise that the excellent customer service and amenities live up to the highest standards and is by far a fun place to visit. The Hospitality Committee will have suggestions for activities to do while in the wonderful city of Las Vegas and tours of the local treatment programs will also be available. Our helpful volunteers are committed to assisting you in a variety of ways. Please, don’t be shy about exercising your networking skills; many long relationships begin and develop at conferences such as this.

Las Vegas is waiting for you! There will be a noticeable boost in attendance, therefore I encourage you to register for the conference and book your flight and hotel early. This will be a memorable experience for you, your colleagues, and any family members who accompany you.

My Best to all,

Shirley Linzy, RNMS
2012 Conference Chair
<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, April 21</td>
<td>8:30 a.m.–5:00 p.m.</td>
<td>Registration Open</td>
</tr>
<tr>
<td></td>
<td>8:00 a.m.–5:00 p.m.</td>
<td>The Certified Medication Assisted Treatment Advocate (CMA) Training Course</td>
</tr>
<tr>
<td></td>
<td>9:00 a.m.–5:00 p.m.</td>
<td>Pack Up &amp; Quit: A Tobacco Cessation Program for Opioid Treatment Programs</td>
</tr>
<tr>
<td></td>
<td>1:00 p.m.–4:00 p.m.</td>
<td>Integrating Hepatitis Therapy in the Nation’s OTPs</td>
</tr>
<tr>
<td></td>
<td>1:00 p.m.–4:00 p.m.</td>
<td>Understanding and Expanding Access to Medication Assisted Treatment in Drug Courts</td>
</tr>
<tr>
<td></td>
<td>1:00 p.m.–4:00 p.m.</td>
<td>Buprenorphine Treatment for Young Adults</td>
</tr>
<tr>
<td></td>
<td>5:00 p.m.–8:30 p.m.</td>
<td>AATOD Open Board Meeting</td>
</tr>
<tr>
<td>Sunday, April 22</td>
<td>7:30 a.m.–7:30 p.m.</td>
<td>Registration Open</td>
</tr>
<tr>
<td></td>
<td>8:00 a.m.–5:30 p.m.</td>
<td>Presentations by the World Federation for the Treatment of Opioid Dependence (WFTOD)</td>
</tr>
<tr>
<td></td>
<td>8:00 a.m.–5:30 p.m.</td>
<td>Opioid Maintenance Pharmacotherapy: A Course for clinicians</td>
</tr>
<tr>
<td></td>
<td>8:30 a.m.–12:30 p.m.</td>
<td>Countering Opioid Stigma: Communicating Messages to Influence Public Perception [max. 40 participants]</td>
</tr>
<tr>
<td></td>
<td>8:30 a.m.–12:30 p.m.</td>
<td>Buprenorphine and Methadone Training for Nurses</td>
</tr>
<tr>
<td></td>
<td>8:30 a.m.–5:00 p.m.</td>
<td>State Opioid Treatment Authorities’ Meeting [Closed Session for State and Federal Officials]</td>
</tr>
<tr>
<td></td>
<td>9:00 a.m.–12:00 p.m.</td>
<td>Opioid Treatment Program Accreditation—Town Hall Meeting</td>
</tr>
<tr>
<td></td>
<td>9:00 a.m.–5:30 p.m.</td>
<td>Wrap-Up Session for NIATx OTP Project [INVITATION ONLY]</td>
</tr>
<tr>
<td></td>
<td>9:30 a.m.–12:00 p.m.</td>
<td>Integrating Medication Assisted Treatment of Opioid Dependence with Primary Care Services</td>
</tr>
<tr>
<td></td>
<td>1:00 p.m.–4:00 p.m.</td>
<td>Enhancing OTP Counselor Education on Hepatitis</td>
</tr>
<tr>
<td></td>
<td>1:00 p.m.–5:00 p.m.</td>
<td>Exhibits</td>
</tr>
<tr>
<td></td>
<td>5:30 p.m.–7:30 p.m.</td>
<td>Welcome Reception</td>
</tr>
<tr>
<td></td>
<td>7:30 p.m.–8:30 p.m.</td>
<td>Methadone Anonymous Meeting [Open]</td>
</tr>
<tr>
<td>Monday, April 23</td>
<td>7:30 a.m.–7:00 p.m.</td>
<td>Registration Open</td>
</tr>
<tr>
<td></td>
<td>7:30 a.m.–8:30 a.m.</td>
<td>Continental Breakfast in Exhibit Hall</td>
</tr>
<tr>
<td></td>
<td>7:30 a.m.–9:30 a.m.</td>
<td>Exhibits</td>
</tr>
<tr>
<td></td>
<td>7:30 a.m.–4:30 p.m.</td>
<td>Posters in Exhibit Hall [Exhibit Hall closed 9:30 a.m.–11:30 a.m.]</td>
</tr>
<tr>
<td></td>
<td>8:45 a.m.–10:15 a.m.</td>
<td>Opening Plenary Session—Challenges and Opportunities for the Field of Addiction Treatment</td>
</tr>
<tr>
<td></td>
<td>10:30 a.m.–12:00 p.m.</td>
<td>Workshop Sessions</td>
</tr>
<tr>
<td></td>
<td>11:30 a.m.–4:30 p.m.</td>
<td>Exhibits</td>
</tr>
<tr>
<td></td>
<td>12:00 p.m.–1:30 p.m.</td>
<td>Lunch [on your own]</td>
</tr>
<tr>
<td></td>
<td>1:30 p.m.–3:00 p.m.</td>
<td>Workshop Sessions / Hot Topic Roundtables</td>
</tr>
<tr>
<td></td>
<td>3:00 p.m.–4:00 p.m.</td>
<td>Exhibitor Networking Break in Exhibit Hall</td>
</tr>
<tr>
<td></td>
<td>4:00 p.m.–5:30 p.m.</td>
<td>Workshop Sessions</td>
</tr>
<tr>
<td></td>
<td>6:30 p.m.–8:00 p.m.</td>
<td>Digital Access to Medication (D-ATM) Town Hall: Using Technology in Opioid Treatment to Prepare for Disasters &amp; Prevent Service Discontinuity</td>
</tr>
<tr>
<td></td>
<td>7:00 p.m.–8:30 p.m.</td>
<td>Methadone Anonymous Meeting [Open]</td>
</tr>
<tr>
<td>Tuesday, April 24</td>
<td>7:30 a.m.–9:00 p.m.</td>
<td>Registration Open</td>
</tr>
<tr>
<td></td>
<td>7:30 a.m.–8:30 a.m.</td>
<td>Continental Breakfast in Exhibit Hall</td>
</tr>
<tr>
<td></td>
<td>7:30 a.m.–8:45 a.m.</td>
<td>Poster Author Session</td>
</tr>
<tr>
<td></td>
<td>7:30 a.m.–1:30 p.m.</td>
<td>Exhibits</td>
</tr>
<tr>
<td></td>
<td>7:30 a.m.–1:30 p.m.</td>
<td>Posters in Exhibit Hall</td>
</tr>
<tr>
<td></td>
<td>8:45 a.m.–10:15 a.m.</td>
<td>Middle Plenary Session—Recovery Oriented Methadone Maintenance: Recovery for Patients, Families and Communities</td>
</tr>
<tr>
<td></td>
<td>10:30 a.m.–12:00 p.m.</td>
<td>Workshop Sessions</td>
</tr>
<tr>
<td></td>
<td>12:00 p.m.–1:30 p.m.</td>
<td>Lunch [on your own]</td>
</tr>
<tr>
<td></td>
<td>1:30 p.m.–3:00 p.m.</td>
<td>Workshop Sessions</td>
</tr>
<tr>
<td></td>
<td>7:00 p.m.–9:30 p.m.</td>
<td>Awards Banquet</td>
</tr>
<tr>
<td></td>
<td>9:30 p.m.–10:30 p.m.</td>
<td>Methadone Anonymous Meeting [Open]</td>
</tr>
<tr>
<td>Wednesday, April 25</td>
<td>7:00 a.m.–1:00 p.m.</td>
<td>Registration Open</td>
</tr>
<tr>
<td></td>
<td>7:00 a.m.–8:00 a.m.</td>
<td>Continental Breakfast</td>
</tr>
<tr>
<td></td>
<td>8:00 a.m.–9:30 a.m.</td>
<td>Workshop Sessions</td>
</tr>
<tr>
<td></td>
<td>9:45 a.m.–11:15 a.m.</td>
<td>Workshop Sessions</td>
</tr>
<tr>
<td></td>
<td>11:30 a.m.–12:45 p.m.</td>
<td>Closing Plenary Session—Health Care Reform and Substance Abuse Treatment</td>
</tr>
<tr>
<td></td>
<td>1:00 p.m.–3:30 p.m.</td>
<td>Clinic Tours [Sign-Up at Hospitality Table]</td>
</tr>
</tbody>
</table>

All events and times listed are subject to change.
Pre-Conference Sessions

Saturday, April 21, 2012

8:00 a.m.–5:00 p.m.

The Certified Medication Assisted Treatment Advocate (CMA) Training Course

Joycelyn Woods, MA, NAMA Recovery, New York, NY
Roxanne Baker, CMA, NAMA Recovery, Santa Cruz, CA
Patricia A. Chambers, RN, HFS IV, Carson City, NV
Walter Ginter, CMA, NAMA Recovery, New York, NY
Kerry Wolf, RN, NAMA Recovery, New York, NY
Nicholas Reuter, MPH, Substance Abuse and Mental Health Services Administration (SAMHSA), Rockville, MD
Laura McNicholas, MD, Philadelphia Veterans Administration Medical Center, Philadelphia, PA
Anthony Scro, MA, NAMA Recovery, New York, NY

The leading advocate and recovery organization for medication assisted treatment, the National Alliance for Medication Assisted Treatment (NAMA Recovery) developed this training, believing that professionals, patients and their families can work together for a better understanding of methadone and medication assisted treatment. Both patients and non-patients are encouraged to become Certified Medication Assisted Treatment Advocates (CMA). The course presentation includes:

Medication Assisted Treatment – Basic clinical information about methadone and buprenorphine treatment.

Addiction and Methadone – Current science about addiction in a language understandable to the non-clinician.

Regulations and Accreditation – Current regulations explained by the federal agency that oversees methadone and buprenorphine treatment and the State Opioid Treatment Authority.

Hands On Advocacy – Basic tools to work as an advocate and how to manage issues that confront advocates and working within communities to benefit patients and treatment.

Advocacy and The Media – Responding to negative content in newspapers, television, movies, etc. by writing response letters and letters to the editor.

Systems Advocacy – Using advocacy to change policy and working within state and federal systems to improve the rights of patients.

The Certified Medication Assisted Treatment Advocate (CMA) – Role of a CMA, ethics of advocacy, the mechanism of certification, and professionalize those committed to advocacy.

The course involves 8 hours of rigorous training and fulfills the training requirement for Certification as a Medication Assisted Treatment Advocate (CMA).

Candidates for certification must register with NAMA Recovery prior to the conference. Registration information is available at: www.methadone.org. There is a separate registration fee for the pre-conference event. Lunch is not provided. NAMA Recovery cannot guarantee a place to anyone not pre-registered.

Sponsored by the National Alliance for Medication Assisted Recovery (NAMA Recovery).

9:00 a.m.–5:00 p.m.

Pack Up & Quit: A Tobacco Cessation Program for Opioid Treatment Programs

Greg Williams, EdD, University of Maryland, Baltimore, MD
Deb Petska, MA, Danya International, Inc., Silver Spring, MD
LT Brandon Johnson, MBA, Substance Abuse and Mental Health Services Administration (SAMHSA), Rockville, MD

This session will provide participants with a variety of materials and assessments that will allow the participants to return to their clinics and determine the readiness and appropriateness of integrating the Pack Up & Quit Program in their clinical services. Specifically, the session will provide an overview of the Pack Up & Quit Program and its fundamental principles: use of adult learning theory, use of the stages of change model, and reliance on a patient-driven cessation program. The participants will learn the requirements of the program for clinics, administrators, staff, and tobacco using participants. They will receive copies of the clinic and tobacco user participant’s contracts for participation in the program. They will also have an opportunity to review all recruitment materials, posters, and other materials as well as the Trainer’s Manual for the program. Participants will complete an actual session (e.g., Session 2: Tobacco Harms and an Introduction to Choosing an NRT) of the six session program for smokers.

Participants will have the opportunity to conduct at least two tobacco cessation session activities exactly as they will be presented in clinics that ultimately adopt the program. Finally, participants will have ample time to ask questions about the program and related issues. All participants will be asked to complete a pre- and post-workshop evaluation (for the presenters’ use) and a tobacco literacy test that will be self-assessed and will not be collected by the presenters.

Sponsored by the Substance Abuse and Mental Health Services Administration (SAMHSA).
An estimated 5.3 million people in the United States live with chronic viral hepatitis (Institute of Medicine [IOM], 2010). Viral hepatitis is often a silent disease whose symptoms and signs become evident only after the disease has caused severe liver damage. As a result, between 2010 and 2019, an estimated 193,100 people in the United States could die of liver cancer or other hepatitis-related liver disease (Wong, McQuillan, McHutchison, & Poynard, 2000).

All people who use or have used illicit substances are at high risk of contracting viral hepatitis. Injection drug use (IDU) is the primary way of contracting hepatitis C. Substance use disorders (SUDs) do not cause viral hepatitis, but people can contract or spread some types of viral hepatitis by sharing needles and other drug paraphernalia. In people who have chronic hepatitis, continued use of alcohol contributes to and frequently accelerates liver damage (Bhattacharya & Shuhart, 2003).

Viral hepatitis can be prevented and treated. Counselors, administrators, and Medical Directors in SUD treatment settings play an important role in promoting the prevention and treatment of viral hepatitis among their patients. Attendees of this session will learn how various opiate agonist treatment staff can integrate viral hepatitis screening, counseling, treatment, and vaccination in their work. They will also learn what new treatments are available for genotype-1 infected patients, and what payment options for hepatitis therapy are available for OTP patients.

Sponsored by the Substance Abuse and Mental Health Services Administration (SAMHSA).

1:00 p.m.–4:00 p.m.

Understanding and Expanding Access to Medication Assisted Treatment in Drug Courts

Doug Marlowe, JD, National Association of Drug Court Professionals, Alexandria, VA
Brian McCarroll, DO, BIOMED Behavioral Healthcare, Clifton Township, MI
The Honorable Robert Ziemian, Drug Court Judge, Boston, MA

The National Association of Drug Court Professionals recently released a position paper in support of expanding the use of Medication Assisted Treatment. This session is designed to educate Drug Court Judges, coordinators, and other staff to increase knowledge concerning federally approved medications to treat chronic opioid addiction. The science, law, and policy around the use of Medication Assisted Treatment for chronic opioid addiction in Drug Court settings will be discussed. All three presenters have worked extensively on this topic and will provide a better understanding of the use of Medication Assisted Treatment in the Drug Court setting.

Sponsored by the American Association for the Treatment of Opioid Dependence, Inc. in collaboration with the National Association of Drug Court Professionals.
Opioid Maintenance Pharmacotherapy: A Course for Clinicians
Laura McNicholas, MD, Philadelphia Veterans Administration Medical Center, Philadelphia, PA
Susan Neshin, MD, JSAS Healthcare, Inc., Neptune, NJ
J. Thomas Payte, MD, Colonial Management Group, LP, Orlando, FL
Trusandra Taylor, MD, JEVS Human Services, Philadelphia, PA
This course is recommended for clinicians with experience and/or interest in the medication assisted treatment of opioid dependence. The updated curriculum includes current consensus guidance for best practice treatment for opioid addiction. Topics include overview of opioid dependence, epidemiology, opioid pharmacology/neurobiology; evidence-based treatment options, patient assessment/selection, special populations, induction and maintenance protocols, pain management, drug-to-drug interactions, adverse effects, methadone deaths, managing medical/psychiatric problems, drug testing, regulatory issues, an accreditation update, risk management and an overview of buprenorphine.

Participants will receive a comprehensive syllabus with reference and resource materials. To further integrate the educational objectives, participants are encouraged to discuss challenging problems, relevant case studies, and clinical issues to facilitate understanding of didactic principles.

Four experienced opioid treatment program medical directors will conduct the program, focusing on the goal for participants to acquire the essential knowledge and skills necessary to deliver safe and effective medication assisted treatment for patients with opioid dependence.

The $225.00 registration fee includes a morning coffee service and afternoon luncheon.

Sponsored by the American Association for the Treatment of Opioid Dependence, Inc.
Supported by the National Institute on Drug Abuse.

Presentations by the World Federation for the Treatment of Opioid Dependence (WFTOD)
The World Federation for the Treatment of Opioid Dependence (WFTOD) was founded during the EUROPAD meeting of July 2007 in Ljubljana, Slovenia. All of the member nations, which included the member countries of EUROPAD and all of the member states within AATOD, agreed to a charter for the World Federation. These presentations represent the broadest inclusion of Medication Assisted Treatment for opioid addiction throughout the world.

8:00 a.m.–8:15 a.m.  INTRODUCTIONS
Michael Rizzi, AATOD International Committee Chair
Icro Maremmani, MD, EUROPAD, President WFTOD
8:15 a.m.–9:30 a.m.  EUROPAD PRESENTATIONS
Analysis of Serotonin, 5-Hydroxyindolacetic and Homovanillic Acid in Dried Blood Spots during Opioid Replacement Therapy
L. Somaini1, M.A. Saracino1, M.C. Pieri1, G. Gerra2, M.L. Gerra1, M. Amore1, M.A. Raggi1
1 Italy, EU  2 Austria, EU

A Multi-level Model of Clinical and Institutional Supervision
A. Kantchelev, T. Stoykova, & O. Todorov, Sofia, Bulgaria, EU

Changes in Guidelines for Maintenance Treatment for Opiate Misusers in Sweden: Effects on Opiate-Related Mortality, Morbidity and Criminality
M. Stenbacka & A. Romelsjö, Stockholm, Sweden, EU

9:30 a.m.–10:45 a.m.  SOUTHEAST ASIA PRESENTATIONS
Methadone Treatment in Vietnam: National, Provincial and Technical Perspectives
Vu Hu Hoang, MD, SAMHSA, US Embassy in Hanoi, Vietnam
Methadone Treatment in Vietnam: From Policy to Implementation
Nguyen Thi Minh Tam, Nguyen Thanh Long & Pham Duc Manh, Vietnam
PRESENTER: Dr. Nguyen Thi Minh Tam, Vietnam Administration of HIV/AIDS Control (VAAC)
Implementing Methadone Maintenance Treatment at the Provincial Level; Challenges and Lessons Learned
Hoang Van Ke, MD, Hai Phong, Vietnam
Clinical Mentoring and Capacity Building for the Scaling up of Methadone Treatment in Vietnam
PRESENTER: Nguyen To Nhu, MD, Family Health International, FHI 360 Vietnam
10:45 a.m.–12:00 p.m.  **AFRICA PRESENTATIONS**

**Recent Efforts to Address Opioid Addiction and Medication Assisted Treatment**

Introducing Medication Assisted Treatment for Opioid Addiction in Dar-es-Salaam, Tanzania

R. Douglas Bruce, MD, Yale School of Medicine AIDS Program, New Haven, CT

Medication Assisted Treatment Models for the Islands of Zanzibar and Mauritius

Sharon Stancliff, MD, Harm Reduction Coalition, New York, NY

**ATTC International Activities**

Introducing ROSC to Patients in Zanzibar and Dar-es-Salaam, Tanzania

Lonnetta Albright, MSW, Great Lakes ATTC at the University of Illinois / Jane Addams College of Social Work, Chicago, IL

Broad Overview on Addressing Opioid Addiction in the Middle East

Richard A. Rawson, PhD, UCLA Integrated Substance Abuse Programs, Los Angeles, CA

12:00 p.m.–1:00 p.m.  **LUNCH**

1:00 p.m.–2:15 p.m.  **SOUTHEAST ASIA PRESENTATIONS**

**SESSION MODERATOR:** Wayne Wiebel, PhD, US Agency for International Development/HCMC

**Methadone & Beyond: Developing a Community-Based System of Support Services for Drug Dependence in Vietnam**

Introduction & Roll-out of Methadone Maintenance Therapy in Ho Chi Minh City (HCMC), Vietnam

Dr. Le Truong Giang, HCMC Provincial AIDS Committee

Integrating Support Services to Enhance Methadone Maintenance Therapy Outcome in Ho Chi Minh City, Vietnam

Ms. Vu Thi Tuong Vi & Dr. Tieu Thi Tu Van; Mr. Nguyen Van Minh & Dr. Wayne Wiebel

**PRESENTER:** Ms. Vu Thi Tuong Vi, HCMC Provincial AIDS Committee, Vietnam

Mobilizing Community Resources for a Pilot Drug Abuse Intervention Initiative in HCMC, Vietnam

Mr. Nguyen Van Minh, HCMC Department of Labor, Invalids and Social Affairs and Dr. Wayne Wiebel, U.S. Agency for International Development/HCMC

**PRESENTER:** Mr. Nguyen Van Minh, HCMC Department of Labor, Invalids & Social Affairs, Vietnam

2:15 p.m.–3:30 p.m.  **EUROPAD PRESENTATIONS**

**Impact of Double-Diagnosis and Illicit Drug Abuse on the Outcome of Hepatitis-C Treatment in Patients on Opiate-Substitution-Therapy (OST)**

S. Walcher, M. Schaefer, B. Weber, S. Mauss, M. Waizmann, A. Breske, Germany, EU

**Anti-Dysphoric Effects of Buprenorphine in the Treatment of Opioid Dependence is a Possible Predictor of Treatment Response**

M. Ferdico¹, R. Cortina¹ & C. Betancur²

¹ Italy, EU  ² France, EU

What happens when Assisted Outpatient Treatment is Terminated?

Treatment Transitions and Crime. Changes in crime rates around treatment termination

A. Bukten, SERAF, Norwegian Centre for Addiction Research, University of Oslo, Norway

**Mortality in a Short- and Long-Term Perspective following Treatment Termination**

T. Clausen, SERAF, Norwegian Centre for Addiction Research, University of Oslo, Norway

3:30 p.m.–4:45 p.m.  **SOUTHEAST ASIA PRESENTATIONS**

**SESSION MODERATOR:** Kevin P. Mulvey, PhD, Substance Abuse and Mental Health Services Administration (SAMHSA)

Implementing Methadone in Resource Limited Environment, Three Countries Perspective: Cambodia, China and Vietnam

Methadone Treatment in Vietnam: From Policy to Implementation

Dr. Nguyen Thi Minh Tam, Nguyen Thanh Long, Pham Duc Manh, Dr. Zhijun Li, Dr. Marc Bulters

**PRESENTER:** Dr. Zhijun Li, Center for Disease Control, China

Challenges of Establishing Evidence-Based Drug Dependence Treatment Services in Cambodia

Dr. Chhit Sophal & Dr. Graham Shaw

**PRESENTER:** Dr. Chhit Sophal, Cambodia MAT Program

Increasing Access to Medication Assisted Treatment in Macao

Celeste Vong, Social Welfare Bureau of MSAR Government; Wilson Hon, Department of Prevention and Treatment for Drug Dependence, Macao

4:45 p.m.–5:15 p.m.  **ROUNDTABLE DISCUSSIONS**

5:15 p.m.–5:30 p.m.  **QUESTIONS & ANSWERS**

**Sponsored by the American Association for the Treatment of Opioid Dependence, Inc., EUROPAD, Substance Abuse and Mental Health Services Administration (SAMHSA) and the World Federation for the Treatment of Opioid Dependence.**
Countering Opioid Stigma: Communicating Messages to Influence Public Perception

Frank J. Carillo, ECG (The Communication Strategy Company), Englewood, NJ

Opioid Treatment Programs and patients have been the target of negative public opinion and adverse media coverage. This has affected our field’s ability to effectively influence national drug policy and present the science of opioid addiction and treatment. This negative public perception has affected the ability to site OTPs in communities, especially with zoning board ordinances and political opposition. This negative public perception has also led to the passing of legislation impacting patients and treatment providers in our system in addition to affecting decisions made in courts of law.

This session will focus on the delivery of several key messages specifically designed to counter the stigma and stereotypes which are deeply imbedded in the perception of opioid addiction and Medication Assisted Treatment. These messages have been refined over the course of many years based on the pilot project, “Communicating Messages that Achieve Results.”

This session is designed for program sponsors, administrators, and community relations personnel who routinely meet and speak with media representatives about this treatment system.

For session effectiveness, participation is limited to the first 40 attendees who arrive for the session.

Sponsored by the Substance Abuse and Mental Health Services Administration (SAMHSA).

Opioid Treatment Program Accreditation—Town Hall Meeting

Megan Marx, MPA, The Joint Commission, Oakbrook Terrace, IL
Mary Cesare-Murphy, PhD, The Joint Commission, Oakbrook Terrace, IL

This pre-conference session is designed to be an open forum for Joint Commission accredited programs to discuss the “Accreditation Nuts & Bolts,” which includes enhanced website with an emphasis on BHC accreditation home page and others; 2012 annual and on-site survey fees; toolkit to help enforce smoke free property; new method to record immediate threat to safety situation; E-App improvements; and free tools that are available to Joint Commission Accredited Organizations.

The participants will also discuss the new BHC standards for programs offering or contracting for primary physical health care; leading practice library; medication reconciliation national safety goal; top BHC accreditation standards compliance issues; flu vaccination challenge and accreditation requirements; the 2012 Accreditation Decision Rules & Revisions to Review & Appeal Procedures for adverse decisions; and OTP Grant Close-out Report.

In addition, presenters will provide a hands-on, interactive care plan development exercise focused on achievement of Joint Commission standards compliance.

Registration for this workshop is open to all Joint Commission Accredited Opioid Treatment Programs. To pre-register for this workshop, please contact Megan Marx at 720-348-0672 or at mmarx@jointcommission.org.

Sponsored by The Joint Commission.

Buprenorphine and Methadone Training for Nurses

Colleen LaBelle, RN, Boston Medical Center, Boston, MA
Sara Azimi-Bolourian, MSN, Substance Abuse and Mental Health Services Administration (SAMHSA), Rockville, MD

This session introduces a new guideline, “Buprenorphine: A Guide for Nurses,” published by the Substance Abuse and Mental Health Services Administration (SAMHSA) as the 30th publication in the Technical Assistant Publication Series (TAP #30). This session is intended to provide Registered Nurses (RNs), Licensed Practical Nurses (LPNs), and Nurse Practitioners (NPs) with general information about buprenorphine products for the pharmacological treatment of opioid addiction. It covers screening, assessment, and diagnosis of opioid dependence and its associated problems and contains detailed protocols for the use of buprenorphine under a variety of clinical scenarios, including the use of buprenorphine with patients who are experiencing co-occurring pain or psychiatric disorders, or chemical dependency involving more than one substance.

The session also provides nurses with a comprehensive overview of nursing roles in screening and assessing the health status of patients who have addiction problems. Moreover, the session emphasizes on nurses’ instrumental roles in the development and ongoing monitoring of treatment plans for patients who are on buprenorphine treatment and counseling and referral for psychosocial treatment. This session will assist nurses in developing improved understanding of the complexities of addictions treatment, and will promote better treatment outcomes by utilizing a team approach to patients’ opioid dependence.

Sponsored by the Substance Abuse and Mental Health Services Administration (SAMHSA).
8:30 a.m.–5:00 p.m.

**State Opioid Treatment Authorities’ Meeting**
(Closed Session for State and Federal Officials)

LT Brandon Johnson, MBA, Substance Abuse and Mental Health Services Administration (SAMHSA), Rockville, MD
Onaje Salim, MA, LPC, Substance Abuse and Mental Health Services Administration (SAMHSA), Rockville, MD
Belinda Greenfield, PhD, NYS OASAS, Bureau of Treatment, New York, NY

**Drug Enforcement Administration**

State Opioid Treatment Authorities

Federal officials, including SAMHSA/CSAT/Division of Pharmacologic Therapies (DPT) staff and State Opioid Treatment Authorities will convene to share information and discuss a variety of topics of interest to both SAMHSA and the States. Issues of mutual concern in the approval and monitoring of Opioid Treatment Programs, including clinical, administrative, financing and regulatory policy topics will be discussed to improve and coordinate joint oversight.

*Sponsored by the Substance Abuse and Mental Health Services Administration (SAMHSA).*

9:00 a.m.–5:30 p.m.

**Wrap-Up Session for NIATx OTP Project**
(INVITATION ONLY)

Kimberly Johnson, MBA, University of Wisconsin, Madison, WI
Lynn Madden, MPA, APT, New Haven, CT
Tom Zastowny, PhD, Webster, NY
Alina Salvatore, RPh, Substance Abuse and Mental Health Services Administration, Rockville, MD

This session will be the wrap up session for the SAMHSA funded NIATx OTP project. The project is a year-long effort for 20 providers to improve access to and retention in treatment. The goal of the day will be to celebrate success, share stories and learn some tools and techniques for spreading improvements through the agency when there are multiple sites and sustaining improvement over time once the project is complete.

The presenters will provide an overview of the project accomplishments and sustaining improvement, followed by participant presentations. The participant presentation topics are subject to change based on the progress of the overall project and their identification of issues they would like to hear from their peers.

*Sponsored by the Substance Abuse and Mental Health Services Administration (SAMHSA).*

9:30 a.m.–12:00 p.m.

**Integrating Medication Assisted Treatment of Opioid Dependence with Primary Care Services**

**MODERATORS:** Udi Ghitza, PhD, Center for the Clinical Trials Network, NIDA, Bethesda, MD
Matthew Burke, MD, Office of Quality and Data, BPHC, HRSA, DHHS, Rockville, MD

Recently there have been a significant number of integration-of-care innovations nationally related to implementing integrated substance abuse screening and medication assisted treatment for opioid dependence in diverse primary care settings. New research findings will be presented along with organizational, workforce, regulatory, policy, and fiscal dynamics necessary to sustain integrated care. The role of electronic health record systems to facilitate care integration of medication assisted treatment with primary care services will also be discussed. Major barriers to the dissemination, implementation and sustainability of integration-of-care models will also be presented.

**Building an Infrastructure of Collaborative Care of Opioid-Addicted Patients in Primary Care**

Christopher Shanahan, MD, Department of Medicine, Boston University School of Medicine, Boston, MA

**Reducing Drug Use by Integrating Care of Opioid Dependence and HIV in HIV Primary Care Settings: Results of the Buprenorphine and Integrated HIV Care Model Demonstration Project (BHIVES) Collaborative**

P. Todd Korthuis, MD, HIV Program, Oregon Health and Science University, Portland, OR

**MAT and HIV Treatment Outcomes among Released HIV-Infected Prisoners**

Frederick L. Altice, MD, Yale School of Medicine, HIV in Prisons Program, Yale University, New Haven, CT

**Integration of Primary Care Services into MAT**

Lawrence S. Brown, Jr., MD, Addiction Research and Treatment Corporation, Brooklyn, NY
Paul McLaughlin, MA, Hartford Dispensary, Manchester, CT
Matthew Burke, MD, Office of Quality and Data, BPHC, HRSA, DHHS, Rockville, MD

*Sponsored by the National Institute on Drug Abuse, the National Drug Abuse Treatment Clinical Trials Network (NIDA/CTN) and Health Resources and Services Administration (HRSA).*
The objective of the session is to provide OTP healthcare providers with information they need to encourage their patients to get vaccinated against hepatitis A and B and adopt behaviors that can help halt the hepatitis epidemic among injection drug users and improve the quality of their lives.

Upon completion of the training, attendees should have a basic understanding of:

- What is hepatitis
- Why patients should get tested for hepatitis C
- How hepatitis is transmitted and treated
- What happens to people with the disease, such as how they find out they have HCV, the natural progression of the virus, and how HCV affects the liver
- When and to whom patients with hepatitis C should be referred for additional healthcare services and support
- Existing and future treatments
- How both health disparities and healthcare disparities faced by underserved populations affect patient outcomes
- The type of information and messages OTP healthcare providers can deliver that promote liver health and help patients take action to prevent, treat, and stop the spread of hepatitis C

Sponsored by the Substance Abuse and Mental Health Services Administration (SAMHSA).

---

**Risk Management Strategies for 2012 and Beyond: Developing Strategies to Ensure Wage and Hour Compliance, Avoid Class and Systemic Claims of Discrimination, and Reduce the Cost of Litigation for OTPs**

Paul J. Siegel, JD, Jackson Lewis, LLP, Melville, NY

Employers face workplace law challenges at every stage of the employment relationship, including hiring and retaining staff, addressing safety issues, ensuring compliance with wage and hour laws, and managing family and medical leave. Given the onslaught of employment litigation nationwide, a comprehensive review of employment policies should be a key component of any organization’s risk management strategy. Employers can proactively manage the myriad of workplace law challenges by developing responsible business practices and training supervisors to promote a culture of compliance.

This session will review the major areas of employment litigation, with a focus on preventive strategies. Participants will learn about recent developments in wage and hour class action claims, recent EEOC initiatives, as well as steps that employers can take to improve employee handbooks and other organizational employment policies.

Employers would be well advised to update how they manage their workforce in today’s far more costly and complex legal environment. Due to budget cuts, staffing woes and operational needs, employers too often neglect human resources issues—resulting in out of date handbooks, unlawful application forms, inadequate documentation of problem workers, failure to engage in an interactive process when confronted with an employee’s medical problems and so many other workplace law challenges. This session will identify areas requiring immediate attention and will suggest remedies, not just worries.

_Sponsored by the American Association for the Treatment of Opioid Dependence, Inc._

---

**Enhancing OTP Counselor Education on Hepatitis**

Betsy Ingram-Diver, MA, Hepatitis C Association, Cloquet, MN

Randy Huard, RN/PHN, Hepatitis C Association, Scotch Plains, NJ

Anthony Campbell, MD, Substance Abuse and Mental Health Services Administration (SAMHSA), Rockville, MD

This session provides participants with the knowledge, strategies, and skills OTP healthcare providers need to educate their patients about the causes, modes of transmission, affect, prevention and treatment options related to hepatitis, and in particular, hepatitis C.

---

**Welcome Reception**

Sunday, April 22, 2012
5:30 p.m. – 7:30 p.m.

The Welcome Reception affords all participants the opportunity to make new professional and personal acquaintances, as well as to enjoy some relaxing time with old friends and colleagues not seen for too long.
The National Conference serves as a central gathering point for the opioid treatment community and offers significant opportunities for exhibiting companies and attendees to interact with other professionals who are devoted to the treatment of opioid dependence throughout the nation and abroad. The registrants will consist of the decision makers in this field who spend over $1 billion annually treating more than 290,000 patients in opioid treatment programs. In order to provide exhibitors with steady exposure to conference attendees, all continental breakfasts, refreshment breaks and poster sessions will be held exclusively in the exhibit area. An Exhibitor’s Networking Event will be held Monday, April 23rd from 3:00–4:00 p.m. to encourage contact and dialogue between opioid treatment professionals and the exhibiting companies.

Exhibit Hours
Sunday, April 22—2:00 p.m.–5:00 p.m.
Monday, April 23—7:30 a.m.–9:30 a.m.; 11:30 a.m.–4:30 p.m.
Tuesday, April 24—7:30 a.m.–1:30 p.m.

Posters are in place at all times when the exhibit hall is open—Authors will present their topic on Tuesday from 7:30 a.m.–8:45 a.m.

Domestic and International posters will provide valuable research findings to treatment providers.

Exhibit and Poster Sessions

POSTER TOPICS INCLUDE:

A System for Data Driven Quality Management in Medication Assisted Treatment—The Baltimore Buprenorphine Initiative Model

Sexual Abuse History—Complex PTSD-OCD and other Co-Morbidities—Prevalence and treatment modalities among methadone maintenance treatment patients

Reducing ER Costs and Improving Access to Primary Care in a MAT Population

The Recovery Process in MAT—Views from MARS Project Peer Leaders

New Jersey-Medication Assisted Treatment Initiative (MATI)

Beating the Challenges to Employment Using an Intensive Short Curriculum, Internship and Job Placement Component with Community Partners

Legal and Organizational Principles of Testing for Drugs

Neutralization of Dependence Behavior as a Rehabilitation Method

Cost Efficiencies and Improved Outcomes with Group vs. Individual Counseling

Benzodiazepine Alternatives or Supplemental Strategies

Training Patients How to Develop Educational-Informational and Social Groups—The NAMA Recovery/MARS Model

Successfully Integrating Care for Persons with Co-Occurring Disorders

An Evidence-Supported Method of Managing Environmental and Internal Cues Associated with Substance Abuse and Abstinence

Partnering with Educational Institutes—A Low Cost-High Impact

Stop Stigma Now—A Collaborative Effort between Patient Advocates, Methadone Professionals, and Interested Parties

Rational for the Practice of Obtaining EKGs on all Methadone Patients in a Public Methadone Treatment Program

Implementation of an Electronic Information System to Enhance Practice at an Opioid Treatment Program

Demographic Differences between Methadone Maintenance Patients with Prescription Opioid Dependence versus Heroin Dependence

Medication Assisted Treatment in the Criminal Justice System

Healthcare Reform

Prevalence and Correlates of Prescription Opioid Injection among OTP Enrollees

Can Parole Officers’ Attitudes Regarding Opioid Replacement Therapy be changed?

Patients’ Reasons for Selecting Outpatient Buprenorphine Treatment over Methadone Maintenance Treatment

Methadone Induction—Balancing Safety with Efficacy to Enhance Retention

A Virtual Place for Us: Finding – and Starting – Online Behavioral Health Communities

Adjusting Treatment to the Patient Perspective—Needs and Preferences

Addressing Hepatitis Infection among Intravenous Drug Users (IVDUs) in Opioid Treatment Programs

Improving Attendance to Specialized Psychiatric Services Offered in a Methadone Treatment Program

Buprenorphine and Pregnancy—A Treatment Provider’s Perspective

Implementing Research in Community Treatment Programs—Findings from a CTN Trial

MOHEPC Alliance Hepatitis C Outreach Program in Providing Full Spectrum of Services Directly to At-Risk Population Groups

The Characteristics and Medication and Medical Care Utilization Patterns of Buprenorphine Recipients

Exhibitors as of October 15, 2011

American Association for the Treatment of Opioid Dependence, Inc.
Addiction Treatment Providers
Alkermes Inc.
Ammon Analytical Laboratory Inc
Atlantic Diagnostic Laboratories
Bendiner & Schlesinger Inc.
C&C Containers, LLC
CARF International
Clinical Science Laboratory Inc.
Covidien — Mallinckrodt
CRC Health
Dominion Diagnostics
Fidelitas Medical IT
Karger Publishers
Method One by Computalogic
Neogen Corporation
Netalytics
Netsmart Technologies Inc
Nutritional Supplements
O.Berk Co. of New England and Kols Containers
OraSure Technologies Inc
Redwood Toxicology Laboratory Inc
Roper
Roxane Laboratories, Inc.
San Diego Reference Laboratory
Scilog, Inc.
SMART Management Inc.
The Joint Commission
Tower Systems Inc
VistaPharm Inc.

Neogen Corporation
Netalytics
Netsmart Technologies Inc
Nutritional Supplements
O.Berk Co. of New England and Kols Containers
OraSure Technologies Inc
Redwood Toxicology Laboratory Inc
Roper
Roxane Laboratories, Inc.
San Diego Reference Laboratory
Scilog, Inc.
SMART Management Inc.
The Joint Commission
Tower Systems Inc
VistaPharm Inc.
**Conference Sessions**

**Monday, April 23, 2012**

8:45 a.m.–10:15 a.m.

**OPENING PLENARY SESSION**

**Challenges and Opportunities for the Field of Addiction Treatment**

**WELCOME AND INTRODUCTIONS** – Shirley Linzy, RNMS, Clinic Director/Supervising Nurse, Dr. Miriam & Sheldon G. Adelson Clinic for Drug Abuse Treatment & Research, Inc., Las Vegas, NV

**WELCOME TO LAS VEGAS, NV** – Deborah A. McBride, MBA, Director, Substance Abuse Prevention and Treatment Agency (SAPTA) Division of Mental Health and Developmental Services, Nevada Department of Health and Human Services, Carson City, NV

**THE STATE OF THE FIELD** – Mark W. Parrino, MPA, President, American Association for the Treatment of Opioid Dependence, Inc., New York, NY

**THE STATE OF NEVADA** – Recovery for Patients, Family and Community – Nevada Puts Recovery First – Honorable Brian Sandoval, Governor, State of Nevada; Kathleen Sandoval, First Lady, State of Nevada

**OPIOID DEPENDENCE:** The United Nations Programs to Provide Solutions; Gilberto Gerra, MD, Director, United Nations Office on Drugs and Crime, Vienna, Austria

As substance use dependence becomes part of national health care reform, the Opening Plenary Session will review AATOD’s projects and keynote efforts in Nevada and across the globe. Ms. Shirley Linzy, Conference Chairperson will welcome conference attendees and provide an overview of this exciting conference. Ms. Linzy will be followed by a very special welcome to Nevada by Deborah McBride, Director of Nevada’s Single State Agency, the Substance Abuse Prevention and Treatment Agency. Following Ms. McBride, Mr. Mark Parrino, AATOD President, will provide an overview of the challenges, opportunities and accomplishments of AATOD over the past eighteen months and into the future. Two special keynotes follow: Governor Brian Sandoval and First Lady Kathleen Sandoval will describe Nevada’s efforts to provide prevention, treatment and recovery services to the citizens of Nevada. And, Dr. Gilberto Gerra will present the global efforts of the United Nations Office on Drugs and Crime to impact on the growing problem of opioid dependence across the world.

10:30 a.m.–12:00 p.m.

**WORKSHOP SESSIONS**

Workshops will offer a chance to review the latest treatment data and health care policies, examine their implications for our patients, and strengthen the skills needed to improve the quality of services.

**Basic Track:** This year we will again be offering a special sequence of workshops designed to act as a refresher for seasoned professionals and to meet the needs of individuals who are new to this field. Those who attend all six sessions listed will receive a special certificate of completion.

**Basic Track Workshop Sessions:** A1, B1, C1, D1, E1 and F1

**A1 Methadone Maintenance 101**

Lesley Dickson, MD, Center for Behavioral Health, Las Vegas, NV

Methadone maintenance treatment has been available for decades; yet many clinicians do not understand how and why it is effective in treating opioid dependence and addiction. The presenter will review the basic elements of opioid agonist treatment; examine the pharmacologic aspects of methadone; present initial screening, admission procedures, and assessment techniques; describe associated medical conditions associated with opioid dependence and addiction; evaluate the efficacy of methadone therapy; and review other opioid agonist treatments.

*Note: Basic Track*

**A2 Beyond MARS—The Training Institute at Albert Einstein College of Medicine**

**MODERATOR:** Ira J. Marion, MA, Albert Einstein College of Medicine, Bronx, NY

**PRESENTERS:**

Sarah Church, PhD, Albert Einstein College of Medicine, Division of Substance Abuse, Bronx, NY

Suzanne Hall-Westcott, MS, Beyond MARS, The MARS Training Institute at Albert Einstein College of Medicine, Bronx, NY

Walter Ginter, CMA, Medication Assisted Recovery Support Project, National Alliance for Medication Assisted (NAMA) Recovery, Bronx, NY

The effectiveness of Peer Recovery Support Services for substance use dependence has been established and is evidence-based. The MARS (Medication Assisted Recovery Support) Peer Recovery Support Services (PRSS) Project is the only national demonstration project targeted specifically to patients in Opioid Treatment Programs. The Beyond MARS Training Institute has recently been established to provide PRSS training for OTPs throughout the nation to replicate the success of the MARS project. The workshop presenters will recruit six new OTPs who wish to have peers/patients and staff trained to replicate the success of the MARS Project, at no cost to the OTPs.
How to Prepare Your OTP for Healthcare Reform: Things you can do!

Abigail Kay, MD, Thomas Jefferson University, Philadelphia, PA
Laura Murray, MD, Northwest Human Services, Philadelphia, PA
Trusandra Taylor, MD, JEVS Human Services, Philadelphia, PA

Healthcare Reform and the transformation of the American healthcare delivery system is impacting OTPs in many ways. Learn how to integrate medication assisted treatment with mainstream healthcare. This workshop will present lessons learned and practical strategies to establish relationships with federally qualified health centers (FQHCs), patient-centered medical homes (PCMH)/healthcare homes, and to improve integration and best practice coordination of care for co-occurring psychiatric disorders. A central theme and essential element of the role of electronic health records (EHRs) with the interface of healthcare reform and opioid treatment programs will be reviewed. Each presenter will provide practical resources for providers.

Beyond the MOTHER Study: Clinical Implications of Treating Pregnant Patients

Karol Kaltenbach, PhD, Jefferson Medical College, Philadelphia, PA
John McCarthy, MD, Bi-Valley Medical Clinic, Carmichael, CA
Lauren Jansson, MD, Johns Hopkins University School of Medicine, Baltimore, MD

The MOTHER study demonstrated the relative safety and efficacy of buprenorphine compared to methadone within the parameters of a rigorous research protocol involving in-patient induction, fetal monitoring, and transitional use of morphine that may be impractical in routine clinical practice. This presentation will include a discussion of the complex issues in developing practical guidelines for the use of buprenorphine in pregnancy; a discussion of an Intrauterine Abstinence Syndrome (IAS) that might occur during maternal opioid withdrawal, complicating either buprenorphine inductions or methadone tapers; and a discussion of results from a study investigating fetal neurobehavioral effects in methadone vs. buprenorphine exposed pregnancies.

Implementing Electronic Health Records, Achieving Meaningful Use

Nicholas Reuter, MPH, Substance Abuse and Mental Health Services Administration, Rockville, MD
Belinda Greenfield, PhD, NYS OASAS, Bureau of Treatment, New York, NY
Lisa Cook, ACSW, Ku Aloha Ola Mau, Honolulu, HI

Both the American Recovery and Reinvestment Act and the Affordable Care Act are driving health systems toward the use of information technology, including electronic health records (EHR) for service delivery, quality improvement, cost containment, and increased patient control of personal health care and related information. There are regulatory and financial challenges that affect how OTPs adopt health information technology and develop interoperable systems. Providers and facilities, including OTPs, can be eligible for incentive payments where they demonstrate “meaningful use” of certified EHR technology.

**Sponsored by the Substance Abuse and Mental Health Services Administration (SAMHSA).**

HOT TOPIC ROUNDTABLES

Hot Topic Roundtables are facilitated discussions that focus on current controversial issues in an informal context. Meet with your colleagues as you learn, challenge, support and share your views with others who may have similar or different opinions, experiences, or interests. Engage in one or more of these facilitated discussions.

Experienced leaders in the field will be facilitating these sessions:

**Recovering Addiction Professionals: Opportunities and Challenges**
Facilitator: Gary L. Fisher, PhD

**Responding to Benzodiazepine Use in MAT Patients**
Facilitator: Ron Jackson, MSW

**Immigrant Population: The Disproportionate Challenges to Access Care in the US**
Facilitator: Guillermo Valenzuela

**Managing Clinic Safety Concerns**
Facilitator: Bettye Harrison

**Medical Cannabis in the OTP: Harm Reduction or Harm Production?**
Facilitator: Kellie Rollins, PhD

**“Those People”—Dignity, Respect, and Compassion in the OTP**
Facilitator: Rick Bingham, LCDC

WORKSHOP SESSIONS

**Project ECHO: A Model for Expanding Community-Based Access to Treatment**

Miriam Komaromy, MD, University of New Mexico School of Medicine, Albuquerque, NM
Sanjeev Arora, MD, University of New Mexico Health Sciences Center, Albuquerque, NM

Project Extension for Community Healthcare Outcomes (ECHO),

POLICY MAKERS LUNCHEON

Monday, April 23, 2012

Supported through a grant from Bendiner & Schlesinger, Inc.
developed at the University of New Mexico, improves access to best practice care for complex health problems such as hepatitis C for underserved populations. Using state-of-the-art multipoint video conferencing technology, best practice protocols, and case based learning, ECHO trains and supports primary care providers to develop knowledge and self-efficacy to deliver complex disease care. This workshop will describe the ECHO model and summarize its success with treating hepatitis C, explain how the ECHO model can be used to treat addiction, and share how the model for treating addictions and HCV can be replicated.

# Genetics Matters! Research that Impacts Future Opioid Dependence Treatment

Elizabeth Ducat, NP, Laboratory of the Biology of Addictive Diseases, Rockefeller University, New York, NY
Mary Jeanne Kreek, MD, Laboratory of the Biology of Addictive Diseases, Rockefeller University, New York, NY
Brenda Ray, NP, Laboratory of the Biology of Addictive Diseases, Rockefeller University, New York, NY

This workshop will discuss recent findings from ongoing genetics research performed at Rockefeller University and/or in collaboration with several MMTs located in New York City, Las Vegas, and Tel Aviv, Israel. Presenters will describe the functional effects of mu-opioid receptor variant A118G in healthy subjects and its potential relevance for future addiction treatment; the association of specific genetic variants with methadone dose required for effective treatment of opioid dependence; and the effect of ethnicity, gender and drug use history on obtaining informed consent for genetics addiction research and the importance of treatment providers in the research process.

# Integrated Care Partners Project: An Integrated, Recovery-focused Care Model for People with Mixed Opioid, Medical, and Mental Disabilities

Alan Mathis, MS, Liberation Programs, Bridgeport/Norwalk, CT
David Stayner, PhD, Yale Program for Recovery and Community Health, Yale School of Medicine, New Haven, CT

The workshop presents first-year findings and lessons learned from the Integrated Care Partners (ICP) pilot project. This multi-disciplinary project serves 60 people with co-occurring addictions, medical, and mental health problems—patients who have previously “fallen through the cracks” between traditionally siloed services, without lasting engagement.

Presenters will describe the integrated, recovery-focused engagement/treatment model employed, findings from structured patient interviews, and other clinical/treatment findings. They will also present lessons learned while building an effective service provision partnership between agencies with divergent treatment specialties and cultures, including challenges and opportunities found in creative dialogue between patient, professional and peer staff, and agency leadership.

4:00 p.m.–5:30 p.m.

WORKSHOP SESSIONS

B1 Treatment Planning M.A.T.R.S.

Mark E. Disselkoen, LCSW, Center for the Application for Substance Abuse Technology at the University of Nevada, Reno, NV
James Von Busch, LPC, Center for the Application for Substance Abuse Technology at the University of Nevada, Reno, NV

The National Institute on Drug Abuse (NIDA) and the Substance Abuse Mental Health Services Administration (SAMHSA) Blending Team developed this course. For this course, the concepts of assessment and treatment planning were “blended” to demonstrate the importance of using a standardized assessment tool when treatment planning. Participants will be introduced to the Addiction Severity Index (ASI) and the electronic version, called the DENS. Highlighted are the basics of treatment planning and case file documentation. Time will be given during the course for participants to practice new treatment planning skills. No previous training in ASI is required. * Note: Basic Track

B2 Is it Possible to Treat the Psychopathology of Heroin Addicts Only with Assisted Outpatient Treatment—(EUROPAD)

Pier Paolo Pani, MD, Public Health Department, Cagliari, Italy
Icro Maremmani, MD, University of Pisa, Vincent P. Dole Dual Diagnosis Unit, ‘Santa Chiara’ University Hospital, Pisa, Italy
Angelo G.I. Maremmani, MD, ‘Santa Chiara’ University Hospital, Pisa Italy

This EUROPAD-sponsored workshop focuses on the prominent psychopathology of heroin addicts and treatment using methadone or buprenorphine. There is recent research evidence that supports an antipsychotic, anxiolytic, antipanic, and mood stabilizing effect of opioid medications. The presenters will discuss three questions: 1.) Does the prominent psychopathology of heroin addicts exist? 2.) What is the specific psychopathology of heroin addicts at treatment entry? 3.) Do methadone and buprenorphine have the same impact on psychopathological symptoms of heroin addicts?
B3  Addressing Resistance to Medication Assisted Treatment

Olivia Ryan, MPA, National Office ATTC, Kansas City, MO
Thomas E. Freese, PhD, Pacific Southwest ATTC, Los Angeles, CA
Laurie J. Krom, MS, National Office ATTC, Kansas City, MO

This presentation will address efforts by the ATTC Network to decrease the gap between research and practice and to influence understanding of factors that enhance uptake of innovations. This presentation outlines how pairing research with innovative dissemination techniques can enhance the use of EBPs related to MAT. The presentation will provide an overview of the Buprenorphine Suite, a training product designed by the ATTC Network to provide the SUD treatment field with the tools to access and adopt NIDA treatment protocols. Additionally this presentation will identify research undertaken by the Network which identifies barriers to providing MAT to minority populations.

B4  Patient Care Coordination and Medication Reconciliation

Marie A. Hardy, CASAC, Beth Israel Medical Center, OTP, New York, NY
Darnell Watson, BA, Beth Israel Medical Center, OTP, New York, NY
Adina Trotman, PA, Beth Israel Medical Center, OTP, New York, NY

Reconciliation of medications taken by a patient in OTP is a critical safety issue. It is crucial for OTP clinics to assure coordination of care among providers, to assure effective methadone medication doses and thoroughly evaluate any contraindicated medication issues. The presenters will describe the scope of problems for one OTP in which 30% of patients are receiving prescriptions for psychotropic and pain medications; address the approach to managing coordination of care and medication reconciliation; and discuss the inter-disciplinary approach to evaluate all medications, coordination of care, and patient education. Examples of evaluations and consents will be provided.

B5  Creating an LGBT Safe Space: Inclusivity Improves Treatment Outcomes

Edward G. Johnson, LPC, Southeast Addiction Technology Transfer Center, Charleston, SC

Lesbian, Gay, Bisexual or Transgender (LGBT) individuals enter treatment programs with a unique set of challenges. Unaddressed, these issues all too often contribute to unsuccessful treatment outcomes. This didactic and experiential workshop will review the general constructs of sexual orientation and gender identity. It will explore the particular issues and life experiences of this frequently hidden minority that have contributed to the development of substance use disorders. Participants will become familiar with interventions specific to the LGBT individuals phase of identity development and will be introduced to ways of creating supportive, affirming and inclusive treatment environments.

6:30 p.m.–8:00 p.m.

Digital Access to Medication (D-ATM) Town Hall: Using Technology in Opioid Treatment to Prepare for Disasters & Prevent Service Discontinuity

Arlene Stanton, PhD, Substance Abuse and Mental Health Services Administration (SAMHSA), Rockville, MD
LT Brandon Johnson, MBA, Substance Abuse and Mental Health Services Administration (SAMHSA), Rockville, MD
Daksha Arora, PhD, Westat, Rockville, MD

SAMHSA’s D-ATM project (“Digital Access to Medication”) was conceived as a technological approach to help ensure OTPs can effectively and safely provide medication to patients who have been displaced from opioid treatment programs (OTPs) where they are normally enrolled. D-ATM was developed in the wake of the attacks of 9-11 and then Katrina, but over time, has evolved as an important tool to support continuity of treatment at OTPs even when dealing with more routine service discontinuities.

As AATOD 2012 convenes, D-ATM will be in its fourth year of the current phase, which has focused on beginning implementation into OTPs across the country. This Town Hall will provide an overview and status report on D-ATM, including recent explorations into enlarging the universe of D-ATM clinics by linking with State systems. Participants will also discuss ‘lessons learned’ with setting up and using the D-ATM system and dealing with real-life disasters in the last few years.

As AATOD 2012 convenes, D-ATM will be in its fourth year of the current phase, which has focused on beginning implementation into OTPs across the country. This Town Hall will provide an overview and status report on D-ATM, including recent explorations into enlarging the universe of D-ATM clinics by linking with State systems. Participants will also discuss ‘lessons learned’ with setting up and using the D-ATM system and dealing with real-life disasters in the last few years.

Representatives of SAMHSA and other Federal and State agencies, members of the D-ATM Steering Committee (including representatives of AATOD, NAMA Recovery, COMPA, SOTAs, and others), and program directors, patients and staff who have had experience in working with D-ATM or in dealing with disasters, large or small, are especially encouraged to attend.

Sponsored by the Substance Abuse and Mental Health Services Administration (SAMHSA).
Conference Sessions

Tuesday, April 24, 2012

8:45 a.m.–10:15 a.m.

MIDDLE PLENARY SESSION

Recovery Oriented Methadone Maintenance: Recovery for Patients, Families and Communities

MODERATOR AND KEYNOTE SPEAKER: H. Westley Clark, MD, JD, MPH, CAS, FASAM, Director, Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration (SAMHSA), Rockville, MD

KEYNOTE SPEAKER: Carol McDaid, Co-Founder and Principal of Capitol Decisions Inc., Washington, DC

A PATIENT PERSPECTIVE ON RECOVERY ORIENTED METHADONE MAINTENANCE: OTP Patient Robin L.

KEYNOTE SPEAKER: William L. White, MA, Senior Research Consultant, Chestnut Health Systems, Bloomington, IL

Just prior to the AATOD conference in Chicago, October 2010, Lisa Mojer-Torres and William White published, Recovery Oriented Methadone Maintenance, their seminal work on recovery and methadone maintenance treatment. Six months later, Lisa lost her courageous battle with cancer but her advocacy work and writing lives on.

The Conference Theme, “Recovery for Patients, Families and Communities” and the implementation of health care reform require renewed focus on recovery, patient expectations and outcomes. This themed plenary session features three leaders and champions of the recovery movement. Moderated by CSAT/SAMHSA Director, Dr. H. Westley Clark, this plenary will focus on recovery and the value of recovery oriented methadone maintenance treatment. He will highlight emphasis on recovery oriented systems of care in our field, as health care reform evolves. Carol McDaid, a Founding Board Member of Faces and Voices of Recovery, who was critical to the passage of the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008, will describe the impact of parity and the importance of integrating recovery into programming. This plenary will hear what recovery means to someone in OTP treatment and how OTP has improved her life. The plenary will conclude with a keynote address from Bill White, whose book, Slaying the Dragon, is the recovery bible. Bill will define recovery oriented methadone maintenance for the field. From different perspectives, each speaker will show how treatment and recovery changes patients’ lives, strengthen families and communities.

10:30 a.m.–12:00 p.m.

WORKSHOP SESSIONS

C1 Meeting the Needs of Patients with Co-Occurring Disorders

Joan E. Zweben, PhD, University of California, San Francisco, CA

This workshop will discuss how counselors can help integrate the treatment of psychiatric disorders into the opioid treatment program. We will discuss addictive behavior and psychiatric problems, barriers to addressing them, prioritization of treatment tasks and appropriate education for patients. We will focus on anxiety disorders (especially PTSD) and mood disorders, and also review screening and assessment of suicide risk from the perspective of agency protocols as well as the role of the counselor. Treatment issues will include psychosocial issues (coping strategies, stigma), medication issues (attitudes, feelings, adherence), and collaboration with physicians.

* Note: Basic Track

C2 Engaging Families in the Recovery Process

John Hamilton, LMFT, Recovery Network of Programs, Bridgeport, CT

Donna Rivera, LADC, Recovery Network of Programs, Bridgeport, CT

Karen Reekie, CAC, Recovery Network of Programs, Bridgeport, CT

Family therapy has been recognized as a highly effective treatment modality in the addiction field for many years yet it has not been widely adopted for the treatment of opioid dependence. This workshop will identify some of the benefits as well as challenges in implementing family involvement in the recovery process and will identify concrete strategies on how to improve your family programs at your agencies. The presenters will describe the process of successful implementation of family involvement in a community treatment agency in Bridgeport, Connecticut and how it significantly improved patient satisfaction and treatment outcomes.

C3 Methadone 201

Laura McNicholas, MD, Philadelphia VAMC, Philadelphia, PA

Susan Neshin, MD, JSAS Healthcare, Inc., Neptune, NJ

Trusandra Taylor, MD, JEVS Human Services, Philadelphia, PA

This interactive workshop is designed for the physician and clinician who have already taken Opioid Maintenance Pharmacotherapy: A Course for Clinicians and is now treating patients in an opioid treatment program involving methadone maintenance. The intent of this workshop is to provide an opportunity for formal instruction as well as sharing of information among participants. Presentations include an update on methadone treatment in the pregnant dependent patient with answers to frequently asked questions and a discussion of the use and abuse of benzodiazepines in the methadone-maintained patient. There will be time for open discussion.

CONTINENTAL BREAKFAST

Tuesday, April 24, 2012, 7:30 a.m.–8:30 a.m.

Sponsored by Reckitt Benckiser Pharmaceuticals, Inc.
C4 Patient Activation: Empowering the Patient’s Full Participation in their Recovery

Suzan Swanton, LCSW-C, Substance Abuse and Mental Health Services Administration (SAMHSA), Rockville, MD
Shannon Taitt, MPA, Substance Abuse and Mental Health Services Administration (SAMHSA), Rockville, MD

The need to incorporate meaningful mechanisms for patients to actively collaborate in their health care is a re-occurring theme in quality health care movements as well as in recovery-oriented systems of care for substance use conditions. Patient activation is a process that emphasizes the patient’s role as an active, equal and meaningful member of the treatment team. Following an overview of SAMHSA’s Recovery Support Services Initiative, this workshop will focus on the knowledge, skills and attitudes needed to embrace patient activation as a critical part of care, and programmatic issues to consider when adopting this innovation into clinical services.

Sponsored by the Substance Abuse and Mental Health Services Administration (SAMHSA).

C5 Utilizing Prescription Monitoring Programs to Enhance Medication Monitoring

Jeffrey D. Baxter, MD, Department of Family Medicine and Community Health, University of Massachusetts Medical School, Shrewsbury, MA
Lisa M. Blanchard, MA, Spectrum Health Systems, Worcester, MA

Monitoring for the misuse of prescription medications with abuse potential is a significant challenge for opioid treatment programs. Prescription monitoring programs provide an invaluable resource for enhancing medication monitoring. This workshop will explore the structure of prescription drug monitoring programs and how they vary across states; demonstrate the capabilities and discuss the limitations of the Massachusetts online prescription drug monitoring program; examine how prescription monitoring programs can be utilized at different stages of treatment; and will discuss how the introduction of the online prescription monitoring program in 2010 has enhanced screening and monitoring of patients through case study examples.

1:30 p.m.–3:00 p.m.

WORKSHOP SESSIONS

D1 Therapeutic Partnerships: The Most Important Evidence-Based Practice

Robert C. Lambert, MA, Connecticut Counseling Centers, Inc., Norwalk, CT

Research indicates that the quality of the therapeutic relationship has a greater effect on patient retention and outcomes than the specific counseling approach used. This workshop will focus on the essential, fundamental counseling skill of forming and maintaining the therapeutic relationship. The presenter will provide an overview of the factors that can impact the therapeutic relationship and the unique challenges involved in enhancing the therapeutic alliance with medication assisted patients within the clinical setting. A key area of focus will be counselor expectancy as a therapeutic factor. Boundary issues specific to the counselor in recovery will also be explored.

* Note: Basic Track

D2 Improving Efficiency and Cost through Patient-Directed Recovery-Oriented Care

Peter Coleman, MS, NYC Health and Hospitals Corporation, New York, NY
Michael Norman Haynes, BA, NYC Health and Hospitals Corporation, New York, NY
Alicia Bartz, MA, NYC Health and Hospitals Corporation, New York, NY

Applying tools from the NIATx change process, the New York City Health and Hospitals Corporation (HHC) transitioned their treatment programs to a chronic care model. This effort resulted in improved access to services, enhanced patient care and support for long term recovery, efficient service delivery, and reduced costs. This workshop will review the basic principles of recovery; examine NIATx change tools; and explain how HHC integrated and operationalized these principles through integrated, multi-disciplinary customizable forms that include mandated data reporting elements, utilize the language of recovery, and facilitate the transfer of patients between programs. Easy, replicable examples will be provided to attendees.

D3 Emergency Management & Planning in OTPs

Megan Marx, MPA, The Joint Commission, Oakbrook Terrace, IL
Deborah Powers, BS, Consultant, Madison, WI
Richard Weisskopf, BS, Illinois Department of Alcoholism and Substance Abuse, Chicago, IL

Developing an Emergency Management Plan is imperative for the well-being of OTP patients and staff. This workshop will focus on the impact of all types of emergencies on program operations and will identify critical elements of an effective emergency management plan including emergency mitigation, preparedness, response and...
recovery. The importance of developing community collaborations to respond to emergencies will also be addressed. Attendees will participate in small group discussions addressing critical communication strategies during an emergency, and how to ensure that patients and staff are notified of emergency procedures and access to care during a crisis.

**D4 Electronic Information System Implementation at an Opioid Treatment Program**

*Lawrence S. Brown, Jr., MD, Addiction Research and Treatment Corporation, Brooklyn, NY*

*Melissa Lin, MS, Addiction Research and Treatment Corporation, Brooklyn NY*

*Steven Kritz, MD, Addiction Research and Treatment Corporation, Brooklyn, NY*

There is considerable discussion about ways to achieve desirable healthcare outcomes cost-effectively. Use of an electronic health information system has been the focus of many of these discussions, though generally not in substance abuse treatment settings. The Addiction Research and Treatment Corporation received a NIDA R01 funding grant to study the implementation of an electronic health information system at our methadone maintenance clinics. This workshop will focus on the roadblocks and challenges to implementation, the findings from the five domains examined by the research study, and areas where we have exploited system capabilities to positively impact patient care.

**D5 The Overdose Prevention Toolkit for Opioid Treatment Programs**

*LT Brandon Johnson, MBA, Substance Abuse and Mental Health Services Administration (SAMHSA), Rockville, MD*

*Fred Brason, II, Project Lazurus, North Wilkesboro, NC*

*Melinda Campopiano, MD, Western Psychiatric Institute and Clinic, Pittsburg, PA*

This session will review the need for overdose prevention programs within the treatment community. Opiate treatment programs and providers are in a unique position to prevent overdose because of their interface with individuals combating opiate addiction and the inherent risk of overdose during medication induction. Overdose prevention within Opioid Treatment Programs may have important implications for reducing overdose-related morbidity and mortality.

*Sponsored by the Substance Abuse and Mental Health Services Administration (SAMHSA).*

---

**Awards Program**

**Tuesday, April 24, 2012**

**7:00 p.m.–9:30 p.m.**

**Introduction to the Awards Program**

Please join us for the centerpiece of our Conference, a moving tribute to those individuals who have been nominated and selected by their peers for extraordinary service in the opioid treatment community. These successful Award recipients have devoted themselves to improving the lives of patients in our treatment system. Dr. Vincent Dole and Dr. Marie Nyswander were the first recipients of this Award in 1983. The Association has been responsible for bestowing this honor since the first Regional Conference of 1984 in New York.

The Nyswander/Dole “Marie” Awards will be presented by Beny J. Primm, MD, Executive Director, Addiction Research and Treatment Corporation, Brooklyn, NY.

The 2012 American Association for the Treatment of Opioid Dependence National Conference recognizes outstanding contributions to opioid treatment by honoring the following individuals with the Nyswander/Dole Award.

**Joseph V. Brady, PhD, Maryland**

During an impressive 50 year career, Dr. Brady made far-reaching contributions to the understanding and treatment of opioid use disorder. Dr. Brady published field-changing work on expanding the traditional approach to methadone treatment by designing the first mobile methadone treatment service in the country. He also founded the Division of Behavioral Biology in the Department of Psychiatry at the Johns Hopkins School of Medicine where he was influential in the development of countless young addiction research scientists. Dr. Brady received the Pacesetter Award from the National Institutes of Health in recognition of his contribution to over 500 research publications and scientific presentations. He was a founding member of the College on Problems in Drug Dependence (CPDD) and was a significant figure in the advancement of methadone maintenance through his pioneering research and mobile methadone delivery programs. His award is being accepted posthumously by his daughter, Kathleen Brady, MD.

**Otto C. Feliu, MS, New York**

For over 30 years, Otto Feliu has been the director of Crouse Health Hospital Chemical Dependency Treatment Services. He also holds a Governor’s appointment to serve on the NY State Advisory Council on Alcoholism and Substance Abuse Services and has served on the Board of Directors of the Committee of Methadone Program Administrators of New York State, Inc. Recognizing that addiction affects the entire family, he is facilitating the implementation of an evidence-based cogni-
tive behavior support group model for family members of patients with substance abuse disorders. Mr. Feliu has been instrumental in ensuring that patients who participate in Drug Court in Onondaga County are allowed to remain in medication assisted treatment. As a clinician, educator, administrator, activist, and community leader, Otto has continued to strive for greater awareness and understanding of the disease of addiction.

**Barbara Schlichting, LCSW, New Jersey**
Ms. Schlichting has devoted her career of almost 40 years to service in the field of addiction treatment. Ms. Schlichting’s work in opioid treatment and her efforts to ensure that all individuals suffering from the disease of addiction receive the most clinically appropriate and affordable treatment available has served as a model of leadership in New Jersey. She has expressed this commitment as a counselor, clinical supervisor, Executive Director of Somerset Treatment Center, and continued her service by accepting leadership roles in the Associated Treatment Providers of New Jersey and as the President of the New Jersey Association for the Treatment of Opioid Dependence. She has served on several state-wide committees and has testified before legislative hearings to bring significant change in the perception of medication assisted treatment and the patients who are receiving these services.

**Edward J. Johnson, MA, South Carolina**
A leader in the field of medication assisted treatment in South Carolina, Edward Johnson helped form and is the current president of the South Carolina Association for the Treatment of Opioid Dependence. Mr. Johnson has been instrumental in providing Hepatitis and HIV workshops, and other vital trainings to virtually every opioid treatment program in the state. Mr. Johnson has fostered a more effective working environment within the state by helping to develop relationships between State officials and OTP staff. Through his chairmanship of the Board of the South Carolina Association of Alcohol and Drug Abuse Counselors, he helped to reduce the stigma associated with medication assisted treatment and provide guidance and influence for the credentialing process of OTP counselors. Mr. Johnson’s many advocacy efforts include supporting patient health and safety and increasing resources to enrich patient care in South Carolina OTPs.

**Hilary Jacobs, MSW, Massachusetts**
Hilary Jacobs is an accomplished Public Health Senior Analyst with an unwavering commitment for medication assisted treatment. Ms. Jacobs has demonstrated proficiency in health care financing and policy, performance management, clinical management, systems development and quality assurance. Her expertise in policy making in government settings and compassionate leadership has changed the landscape for methadone treatment patients and providers in Massachusetts. She is a clinician with 30 years of direct care and administrative experience in addiction treatment. She is well respected by her colleagues who describe her as fair, thoughtful, dedicated and generous. Ms. Jacobs has been a Program Director at North Charles, Inc. before becoming the Deputy Director of the Bureau of Substance Abuse Services, Department of Public Health in Massachusetts.

**Stacy Seikel, MD, Florida**
Dr. Stacy Seikel is currently the Medical Director at the Center for Drug Free Living. She serves as a PCSS Mentor for Buprenorphine, has co-authored an addiction medicine chapter in a family practice physician textbook, and is a frequent presenter at state and national conferences. She has served in leadership roles for the Florida Society of Addiction Medicine and the American Society of Addiction Medicine, where she worked to educate and reduce the stigma associated with medication assisted treatment. In addition, Dr. Seikel has been lauded for advancing the Florida Prescription Monitoring Program, her advocacy for pregnant and post partum opioid addicted women and their babies, and the development of a medication assisted treatment program in a local Florida jail. Aside from being frequently interviewed by media concerning addiction and opioid dependence, she is known by colleagues to provide compassionate care and exhibits a true empathy for her patients.

**Steve Tapscott, MA, Texas**
During his more than 30 years as a CEO, manager and sponsor of Texas Treatment Centers, Mr. Steve Tapscott has become widely known for his strong advocacy for patient rights, evidence-based care, patient empowerment and increased accessibility of treatment. He was the founder and chairman of the Texas Methadone Treatment Association and was co-founder and CEO of the Texas Opioid Treatment Alliance. He has also served as a past Texas representative on the AATOD Board of Directors. In the hectic days following Hurricane Katrina, Mr. Tapscott rented a large van and drove numerous daily round trips to ensure that displaced Louisiana methadone patients received appropriate continuity of care during that emergency. Mr. Tapscott created the first patient advocacy group in Texas and has organized numerous state patient/provider conferences and fundraisers.

**Stephan Walcher, MD, Germany**
Dr. Walcher is a specialist in anesthesiology, intensive care and addiction medicine. Working in the addiction field since 1981, Dr. Walcher has operated the largest opioid treatment program in southern Germany. In his program, he successfully integrated drug treatment services with the treatment of infectious diseases, as well as providing psychosocial support, psychiatric services and access to general medicine. He is the co-founder and long-time chair of the German Association of Addiction Medicine and the Bavarian Academy of Addiction; he also is on the Board of Directors of the European Opiate Addiction Treatment Association.
William C. Wilson, California

As a pioneer in medication assisted treatment, William Wilson established the first in-patient detoxification program in Southern California in the 1960s at Olive View Hospital. Shortly thereafter, he opened a second 30 bed facility in Rosemont. Mr. Wilson wrote and established the first protocol for outpatient methadone maintenance in California, which led to the opening of the Narcotics Prevention Project, the first program in California to be approved for the use of methadone. Mr. Wilson has been a tireless advocate of patient rights and patient access to treatment. Mr. Wilson's work with law enforcement, politicians, state regulators, and the community has changed attitudes about addiction and remains an impressive testimony to his dedication to patients and the field.

FRIEND OF THE FIELD AWARD

The prestigious Friend of the Field Award was established by AATOD’s Board of Directors. This award recognizes extraordinary contributions to the field of opioid treatment by an individual or institution whose work, although not directly related to opioid treatment, has had a significant impact on our field. The 2012 Friend of the Field Award has been awarded to:

William White, MA

William L. (“Bill”) White, Senior Research Consultant at Chestnut Health Systems, has worked full time in the addiction treatment field since 1969 as a community activist, counselor, clinical director, administrator, and research associate. He was one of the founding staff members of Lighthouse (Chestnut Health Systems, 1973) and, following positions in Chicago and Washington, D.C., returned in 1986 to start Chestnut’s research and training division. He has provided training and consultation in 45 states and in Asia and Europe. Bill has authored or co-authored more than 300 articles, monographs, research reports and book chapters as well as 16 books. Bill’s book, *Slaying the Dragon—The History of Addiction Treatment and Recovery in America* received the McGovern Family Foundation Award for the best book on addiction recovery. Bill has also authored or co-authored books/monographs detailing the histories of the New York State Inebriate Asylum, and recovery among Native American tribal communities. His other books focus on such diverse subjects as promoting organizational health of addiction treatment institutions, ethical issues in addiction counseling, American cultures of addiction and recovery and the Chicago model of AIDS case management.

Bill is the past-chair of Recovery Communities United and has served as a volunteer consultant to Faces and Voices of Recovery since its inception in 2001. Bill was featured in the Bill Moyers’ PBS special *Close To Home: Addiction in America* and Showtime’s documentary *Smoking, Drinking and Drugging in the 20th Century* and served as a consultant to the 2007 HBO special *Addiction*. His sustained contributions to the field have been acknowledged by many awards.

RICHARD LANE/ROBERT HOLDEN PATIENT ADVOCACY AWARD

Richard Lane was a long-term heroin user who, upon release from prison in 1967, was instrumental in establishing one of the Nation’s first methadone treatment programs. In 1974, he became the Executive Director of Man Alive and later served as Vice President of the American Methadone Treatment Association and as Vice Chairman of the Governor’s Council on Alcohol and Drug Abuse in Maryland. Mr. Lane was a passionate advocate for methadone treatment and, by disclosing his own treatment experiences, provided inspiration to patients and colleagues alike.

Robert Holden was also a recovering heroin user, who later became the Director of PIDARC, an outpatient methadone treatment program in the District of Columbia. He later served as the Vice President of AATOD, succeeding Richard Lane’s term of office. This award was established in 1995 and recognizes extraordinary achievements in patient advocacy.

Roxanne Baker

As a tireless fighter for medication assisted treatment and the rights and dignity of patients, Roxanne Baker has for the last three years served as President of the National Alliance for Medication Assisted Recovery, Inc. (NAMA Recovery). Ms. Baker’s work on minimizing discrimination through efforts to eradicate stigmatizing language is legendary in the advocacy community, who has often referred to her affectionately as the “language police.” Ms. Baker’s lifetime of volunteer work includes serving as a moderator on two web-based peer self-help recovery lists and fearlessly advocating for needle exchange programs in California. She has presented workshops at AATOD conferences, at Certified Methadone Advocate trainings and at other events across the country with an infectious enthusiasm. As a member of the California Narcotic Treatment Program Advisory Committee, Ms. Baker is a stalwart when it comes to ensuring the goal of every deliberation is improvement of patient care and the assurance of dignity and respect in the treatment setting. Ms. Baker continues to work with many patients as an ombudsman, making herself available to mediate program disputes and teaching patients to be empowered to advocate for themselves as part of their own recovery. Ms. Baker serves as a model and mentor to all who seek to put patients and their welfare at the center of medication assisted treatment.
**Conference Sessions**

**Wednesday, April 25, 2012**

**8:00 a.m.–9:30 a.m.**

**WORKSHOP SESSIONS**

**E1 Recovery Partnerships: Developing and Integrating Peer Mentoring within MAT**

Robert C. Lambert, MA, Connecticut Counseling Centers, Inc., Norwalk, CT
Kurt Kemmling, CMA, CT Chapter National Alliance Methadone Advocates, Berlin, CT

This workshop will focus on the development, implementation, and integration of peer mentoring services within a methadone treatment program with a specific focus on strengthening the therapeutic alliance between the patient and the program. Potential benefits relating to patient outcomes and staff utilization management will be discussed. Short video clips of mentoring sessions will be presented followed by an interactive case discussion between the Peer Mentor and the workshop participants. The presenters will also focus on providing information that the workshop participants will need to replicate all or part of the initiative at their own programs.

*Note: Basic Track*

**E2 Integrating Evidence-Based Therapies for Co-Occurring Disorders**

Mark McGovern, PhD, Dartmouth Medical School, Lebanon, NH
Paul McLaughlin, MA, Hartford Dispensary, Manchester, CT
Aliza Castro, LCSW, Hartford Dispensary, Hartford, CT

This workshop describes an integrated combined therapy (ICT) for co-occurring substance use and psychiatric disorders. The results of a randomized controlled trial comparing ICT to enhanced dual diagnosis services in a community methadone clinic are presented. ICT was delivered by counselors employed by the methadone program with high school to master’s level education. The enhanced dual diagnosis services were provided by experienced doctoral and master’s level clinicians. The findings from the randomized clinical trial are discussed from several vantage points: research, clinical, administrative, training and clinical supervision. Overall, ICT appears effective in reducing psychiatric and substance use severity.

**E3 Methadone from Las Vegas & Tel Aviv to Macao, from Minneapolis to Vietnam**

Einat Peles, PhD, Dr. Miriam & Sheldon G. Adelson Clinic for Drug Abuse, Treatment & Research, Tel-Aviv Sourasky Medical Center, Tel Aviv University, Tel-Aviv, Israel
Hon Wai Wilson, BA, Division for Treatment and Rehabilitation of Drug Dependence, Social Welfare Bureau, Government of Macao Special Administrative Region, People’s Republic of China
Gavin Bart, MD, Division of Addiction Medicine, Hennepin County Medical Center, Minneapolis, MN

Opioid dependent individuals, their families, and communities throughout the world are benefiting from the development, expansion, and implementation of Methadone Maintenance Treatment (MMT). The similarity and differences with respect to guidelines and regulations, patient characteristics and outcomes will be described for: two “Adelson” clinics (Tel-Aviv, Israel and Las Vegas, Nevada); the first MMT program in Macao, founded in collaboration with the “Adelson” clinics; and MMT programs established in Vietnam, and a methadone clinic in Minneapolis, Minnesota that serves a large population of Southeast Asians.

**E4 Delivering Successful MAT Services to Persons with Chronic Pain**

Holly Hills, PhD, University of South Florida, Tampa, FL
Tara Richards, PhD(c), University of South Florida, Tampa, FL
Andre Benson, MD, Operation PAR, Port Richey, FL

One of the most common co-morbidities seen in individuals with opioid dependence is chronic pain. This workshop will review the literature related to the intersection between pain experience and opioid dependence. Presenters will examine findings from recently analyzed administrative data for persons in MAT care. Results describe the percentage of individuals whose opioid dependence was initiated after being prescribed pain medication following an accident, injury, or illness. Frequently documented co-occurring physical health diagnoses were also examined. Clinical challenges, opportunities associated with addressing chronic pain issues while treating opioid dependence, and clinical case examples will also be provided and discussed.

**E5 Mindfulness Based Stress Reduction: A Means for Reducing Substance Use**

Robert Sterling, PhD, Thomas Jefferson University, Philadelphia, PA
Stephen Weinstein, PhD, Thomas Jefferson University, Philadelphia, PA
Kate Vandergrift, MA, Thomas Jefferson University, Philadelphia, PA

Benzodiazepine use represents one of the most vexing problems confronting medication assisted treatment (MAT) providers with estimates indicating that anywhere from 30 to 70% of individuals in MAT will abuse benzodiazepines at some point. The purpose of this workshop is a demonstration of how the MAT programs of Thomas Jefferson University have implemented/integrated a mindfulness based stress reduction (MBSR) intervention into the treatment and recovery process. Close attention will be paid to MBSR’s efficacy with pregnant opiate addicted women. Preliminary outcome data will be presented. Means for training staff and implementing MBSR into the environment of care will be addressed.
New Issues in the Diagnosis and Treatment of HCV

MODERATOR: Richard A Denisco, MD, Services Research Branch, DESPR, NIDA, Rockville, MD

PRESENTERS:
- Uriel R. Felsen, MD, Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY
- Jeanette M. Tetrault, MD, Yale University School of Medicine, New Haven, CT
- Brian Pearlman, MD, Atlanta Medical Center, Atlanta, GA

Over 5 million people are chronically infected with viral hepatitis in the United States, with 2.7 to 3.9 million of those infected with hepatitis C virus (HCV). Over the last two decades, significant advances have been made in the diagnosis, treatment and adjuvant treatment of HCV. This year in fact, two medications have received FDA approval for HCV treatment that have improved HCV clearance or remission by over 25%. This combination of advances for HCV care make this an ideal time to update clinicians on improvements and coverage available to their patients.

* Note: Basic Track

Medication Assisted Treatment Implementation in Community Correctional Environments (MATICCE): Preliminary Findings

Kevin Knight, PhD, Texas Christian University, Fort Worth, TX
Lori Ducharme, PhD, Division of Epidemiology, Services & Prevention Research, National Institute on Drug Abuse, Bethesda, MD
Peter Friedman, MD, Rhode Island Hospital/Providence VAMC, Providence, RI

CJDATS II is a NIDA-funded five-year project that provides a platform for conducting implementation research in criminal justice settings. The MATICCE study engages correctional systems and community-based treatment providers in an implementation intervention that emphasizes staff training on the value of medication assisted treatment, and strategic planning to improve interorganizational linkages. These staff- and organizational-level interventions are expected to benefit offenders as measured by referral rates, treatment receipt, drug use outcomes, and recidivism. The implementation strategies provide a model for broader uptake of MAT, and for balancing public health and safety priorities in resource-constrained systems. This panel provides summaries of preliminary findings.

Shaping Our Future: Updates and Opportunities for the Addiction Care Field

Paul Samuels, JD, Legal Action Center, New York, NY
Gabrielle de la Gueronniere, JD, Legal Action Center, Washington, DC
Dan Belnap, MA, Legal Action Center, Washington, DC

The health care system in this country is currently in a period of tremendous change. Just over a year and a half remains before the major provisions of the Affordable Care Act take effect. These changes have significant implications for the treatment delivery system, and increased coverage for critical drug and alcohol-related services means more people in need of treatment will be able to access it. This workshop will discuss current and future federal developments related to addiction treatment, the future of medication assisted treatment, delivery system reforms, and opportunities available for improving federal policy moving forward.

Comprehensive Treatment of the Pregnant Substance User

Van L. King, MD, Johns Hopkins Bayview Medical Center, Baltimore, MD
Neeraj Gandotra, MD, Johns Hopkins Bayview Medical Center, Baltimore, MD

Treatment of substance dependence is often challenging, and this challenge is even greater when complicated by pregnancy. Workshop leaders will describe the Center for Addiction and Pregnancy adaptive stepped care substance abuse treatment model, and how this model can be used to address substance use problems. Additional discussions will include: patient demographics, rates of specific drug use and psychiatric co-occurring disorders; medication management; collaborations with hospital services and community-based residential treatment services; research findings detailing the risks and long-term adverse outcomes of in-utero exposure to drugs and/or alcohol; and barriers to care that interfere with treatment for pregnant women.
F5 Engaging Veterans and Families across the Lifespan

Kellie Rollins, PsyD, San Francisco VA Medical Center, San Francisco, CA
John Straznickas, MD, San Francisco VA Medical Center, San Francisco, CA
Susan Storti, PhD, Behavioral Health Consultant, Cranston, RI

To date, over 1.8 million veterans have been deployed to the current conflicts. There are over 23 million living veterans. The majority are seeking treatment outside of VA settings. This workshop will enhance provider’s skills in engaging veterans in care. The presenters will describe military culture and its importance in treating veterans; discuss the specific challenges military members, veterans, and their families endure throughout the deployment cycle; and identify effective treatment practices that address the unique challenges of engaging younger veterans.

11:30 a.m.–12:45 p.m.

CLOSING PLENARY SESSION

Health Care Reform and Substance Abuse Treatment

KEYNOTE ADDRESS:

OTPs and the Substance Use Dependence Benefit in the Patient Protection and Affordable Care Act—What OTPs should do now
Howard K. Koh, MD, MPH, Assistant Secretary for Health, U.S. Department of Health and Human Services, Washington, DC (Invited)

KEYNOTE ADDRESS:

Health Care Reform and Substance Abuse Treatment
Harry Reid, Senate Majority Leader, Senator, State of Nevada, Carson City, NV and Washington, DC (Invited)

The Closing Plenary Session will feature two major keynote addresses that cannot be missed for advocates, stakeholders, providers and patients. Howard K. Koh, MD, MPH, Assistant Secretary for Health, U.S. Department of Health and Human Services is the key federal official charged with the implementation of the Patient Protection and Affordable Care Act (ACA). Dr. Koh will outline the provisions of the ACA related to behavioral health, substance abuse treatment, and, specifically, OTPs. Behavioral health parity and the ACA will broaden insurance for patients and make it possible for patients to better access the care they need. We will hear about new entities being created to work with disadvantaged persons such as Accountable Care Organizations, Patient Centered Medical Homes and Health Homes, three possible ways that may allow OTPs to be involved with integrated care.

The United States Senate Majority Leader, Harry Reid, who together with President Obama helped make health care reform a reality, will deliver an inspiring and important Plenary Keynote on health care reform as well as speaking to us about the valuable and important work we do every day. Senator Reid will provide a vision for our future that is not to be missed! Make sure that your plans make it possible for you to be at this important event!

Passing the Baton—Announcement of 2013 Conference Site
Mark Parrino, MPA & Shirley Linzy, RNMS

AATOD traditionally closes each conference with our Conference Chair, Shirley Linzy, and AATOD Board President, Mark W. Parrino handing the “baton” over to the next conference which will be held in November 2013!

1:00 p.m.–3:30 p.m.

CLINIC TOURS

Visit the Hospitality Table on-site for more information and to sign up.
Your visit to Las Vegas will offer an experience of a lifetime. Our city has it all. Dining with world renowned chefs, shopping at the most exclusive stores, world famous gaming, the best entertainment in the world as well as our natural outdoors within the Spring Mountains. Yes, we even have skiing available only 45 minutes from downtown Las Vegas. Where else in the world can you find indoor and outdoor skydiving?

The over six-mile walk along the Strip is a day activity into itself for each hotel property is an attraction to behold. Your conference is in the Venetian | Palazzo Hotel and is a destination onto itself. It is truly a trip to Venice with the fountains, the beautiful artwork, the gaslights and yes, the two canals with gondola rides.

As you walk through the properties, you will find that you can keep your hands in your pocket for taking in the sights is free of charge with the exception of tossing a few coins into the fountains for good luck. Important to note is that the coins are donated to a clinic supporting those addicted to opiates.

Getting around town is very easy to do. There is bus service to all locations at a cost of $2 per trip (now you know why the bus is called the Deuce) with day passes and three-day passes available. The Monorail will connect you to many locations and the taxi service is readily available as well. However, you will easily see that walking is the residents preferred mode of transportation for it is also our best way to people watch.

Once you leave the Venetian | Palazzo you can see the Sirens of TI at Treasure Island, directly across the street. Walk through Caesars Palace for great shopping, and the free shows around the fountains. A must stop are the gardens off the lobby in the Bellagio. Take the free hotel monorail that connects the Bellagio to City Center. Everyone enjoys seeing the lions inside the MGM hotel.

If you head to Circus Circus, the daily Big Top acts are free of charge. Oh, the Paris hotel and its Eiffel Tower are one of the best photo opportunities in town. A walk through the M&M store is another must for you will not believe all the items with the candy logo. While walking around town, celebrity spotting is a great local pastime.

A trip to our valley will not be complete without a side trip to one of our outdoor experiences. You can book day trips by coach or plane to the Grand Canyon. Zion National Park is less than a three-hour car ride from Las Vegas. Or consider taking a ride through historic Boulder City which is minutes from Hoover Dam where you can stand in Nevada and Arizona at the same time, well, depending on daylight savings time. For those with an additional day, Los Angeles is only a 4.5 hour car ride away.
Less than a half-hour from the Strip is a local favorite place, Red Rock National Preserve. Here you can hike or take a 45-minute drive around this magnificent park. If time is limited, then we suggest a visit to Calico Basin, a park, free of charge. There are trails and a boardwalk for those who are less adventurous. We have over 60 golf courses and over 50 public parks in the city. Interested in visiting a winery, Parump Winery is a 50-minute car ride from the Strip.

Looking for an educational experience about the desert, ecology and a great place for lunch, try The Springs Preserve. So what was it like to be in Las Vegas in the 1950s, might we suggest the Atomic Energy Museum? The Fremont Street Experience is a light show that occurs every half hour after dark. While on Fremont Street, stop into the Golden Nugget. There is a shark and fish tank in the middle of the swimming pool. If you are seeking Elvis, this is the place where you will have your choice of “Kings” for your photo to send home. For those interested, a visit to our retro Art District is well worth the time.

Come join us for our outdoor and indoor adventures. You will experience for yourself why we are a 24-hour a day destination. Our committee will be available to you throughout the conference to act as your personal concierge.

Submitted by: Paul & Sandy Schiffman, 2012 Hospitality Committee

---

Hotel Information

The Venetian | The Palazzo
The Palazzo Resort Hotel Casino
3325 Las Vegas Blvd. South, Las Vegas, NV 89109
Phone: 702-607-7777

All sleeping rooms have been reserved in the Palazzo Tower of the property. Palazzo Suite rates have been reserved for attendees at a conference rate of $145 single/double occupancy in a standard suite. This reduced rate is available until Friday, March 30, 2012, subject to availability. Reservation requests received after the cut off date of Friday, March 30, 2012, will be based on availability at the Hotel’s prevailing rates. An optional resort fee of $12.00 per night can be added to your sleeping room rate. If you choose to add the resort fee, it will include: unlimited local and toll free calls, unlimited in-suite internet access, daily newspaper and access to Canyon Ranch fitness center for two adults. Please note that one night’s deposit will be charged to the credit card on file 14 days prior to your arrival. Cancellations are accepted for a full refund up to 14 days before your arrival.

To reserve a room at the group rate, please click on the link on the Conference section of the AATOD website or contact the hotel directly by calling their reservation line at 1-866-659-9659. Please be sure to reference the American Association for the Treatment of Opioid Dependence or AATOD National Conference.

GROUND TRANSPORTATION: Getting around couldn’t be easier. McCarran International Airport’s recent $500 million expansion unveiled one of the most modern airports in the country. Shuttles offer 24 hour services from the airport to Downtown or the Strip, and taxis are always plentiful.
Conference Information

CONFERENCe CONTACTS

TALLEY MANAGEMENT GROUP, INC.
Jessica Shea, CMP, Assistant Director, Meetings & Events
19 Mantua Road
Mount Royal, New Jersey 08061
Phone: 856-423-3091
Fax: 856-423-3420
E-mail: aatod@talley.com
Website: www.aatod.org

EXHIBIT SALES INFORMATION

Sue Parker, Sales Associate
sparker@talley.com

CONTINUING EDUCATION CREDITS

AATOD, Provider #1044, is approved as a provider for social work continuing education by the Association of Social Work Boards (ASWB).

AATOD is an approved provider through the National Association of Alcoholism and Drug Abuse Counselors (NAADAC), Provider #000218.

AATOD is an approved provider through the State of California Board of Behavioral Science, Provider # 4101.

Application has been made to The Center for the Application of Substance Abuse Technology at the University of Nevada, Reno, NV, which houses the Mountain West Addiction Technology Transfer Center (CASAT / Mountain West ATTC) to award Continuing Education Credits for the following specialties:

  - Counseling
  - Marriage and Family Therapy
  - Nursing
  - Physicians

Registration Info & Fees

HOW TO REGISTER:

Registration for the American Association for the Treatment of Opioid Dependence, Inc. (AATOD) National Conference can be done on-line by visiting the AATOD website at www.aatod.org or by completing the registration form on the inside back cover and faxing it to 856-423-3420 or by mailing it to:

AATOD 2012 National Conference Registration
C/o Talley Management Group, Inc.
19 Mantua Road
Mt. Royal, NJ 08061

If faxing your registration, DO NOT mail the original form, doing so may result in duplicate charges to your credit card! Should you have any questions regarding conference registration please call 856-423-3091.

* Includes: Admission to Pre-Conference Sessions (excluding CMA Training Course and Clinicians Course), Welcome Reception, all Plenary Sessions, Workshops, daily continental breakfast, Exhibitors Networking Refreshment Break, and Awards Banquet.

There can be no conference registration fee splitting. Only one discount per conference participant is allowed, including the presenter’s discount.

<table>
<thead>
<tr>
<th>Full Conference Registration *</th>
<th>1 person from an agency</th>
<th>2 or more from an agency, each</th>
</tr>
</thead>
<tbody>
<tr>
<td>Standard Registration until March 30, 2012</td>
<td>$500.00</td>
<td>$475.00</td>
</tr>
<tr>
<td>On-Site April 21, 2012</td>
<td>$575.00</td>
<td>No Group Discount Applies</td>
</tr>
</tbody>
</table>

GROUP DISCOUNTS DO NOT APPLY FOR THE FOLLOWING CATEGORIES:

  - Single Day Registration (Does NOT include Awards Banquet) ................... $250.00
  - Clinicians Course .................................................. $225.00
  - Additional Awards Banquet Tickets ................................ .................. $ 75.00
  - Additional Welcome Reception Tickets .............................................. $ 30.00

CME/CEH FEES

These fees are not included in full conference registration fee

  - Physicians/Physician Assistants/Pharmacists .............................................. $ 45.00
  - Nurses/Social Workers/Psychologists ................................................... $ 35.00
  - Counselors .................................................. $ 25.00

AUDIO RECORDINGS

This year AATOD has again contracted to have all conference sessions recorded. Order the recordings in advance and save up to $90 on all session recordings. Pre-order recordings in advance and pay $100 for Pre-Conference Sessions and $100 for Regular Conference Sessions, a savings of $45 per set. Order in advance and save.

SPECIAL NEEDS

The American Association for the Treatment of Opioid Dependence wishes to take steps to ensure that no disabled person is excluded, denied services, segregated, or otherwise treated differently than other individuals because of the absence of auxiliary aids and services. If you require any auxiliary aids or services identified in the Americans with Disabilities Act, please indicate so on your registration form.
Registration Form

NATIONAL CONFERENCE
April 21–25, 2012 • The Venetian | The Palazzo

Use one form for each registrant. Photocopies of the form are acceptable. Please register on-line at www.aatod.org and click on the ON-LINE REGISTRATION link or complete the registration form.

You may now register two or more from an Agency through the AATOD website.

CONTACT INFORMATION: Please print. Bold fields will print on badge.

First (Given) Name ___________________________  MI ___________________________  Last (Family) Name ___________________________

Name on Badge ___________________________  Affiliation (Employer) ___________________________

Position/Title ___________________________  Degree ___________________________

Business Address ___________________________  City ___________________________  State/Province ___________________________  Country ___________________________  Zip Code ___________________________

Business Telephone ___________________________  Fax Number ___________________________

E-Mail Address ___________________________

Please check only the professional designation that applies:

☐ Administrative/Management  ☐ Policy
☐ Clinical/Medical  ☐ Research
☐ Counseling  ☐ Other (Please Specify)
☐ Funding/Evaluation

FULL CONFERENCE REGISTRATION:
Includes Welcome Reception and Awards Banquet (check all that apply)

☐ One person from an agency $500 $575 $ ________
☐ Two or more from an agency, each $475 $575 $ ________
☐ Single Day (specify day below) $250 $250 $ ________

☐ Saturday  ☐ Sunday  ☐ Monday
☐ Tuesday (Does not include Awards Banquet)  ☐ Wednesday
☐ Yes, I will be attending the Welcome Reception
☐ No, I will not attend the Welcome Reception
☐ Yes, I will be attending the Awards Banquet
☐ No, I will not attend the Awards Banquet

☐ Clinicians Course $225 $ ________
☐ Additional Awards Banquet tickets $ 75 $ ________
☐ Additional Welcome Reception tickets $ 30 $ ________

CME/CEH Fees (Not included in conference registration fee)

Please indicate the type of continuing education units you intend to seek:

☐ Physicians  ☐ Physician Assistants  ☐ Pharmacists $45 $ ________
☐ Nurses  ☐ Social Workers  ☐ Psychologists $35 $ ________

☐ Social Worker License #_____________________ State of Licensure ___________________________

☐ Counselors $25 $ ________

SESSION RECORDINGS
Pre-conference Session Recordings (advance order price $100) ☐ MP3  ☐ CD $ ________
Regular Conference Session Recordings (advance order price $100) ☐ MP3  ☐ CD $ ________

TOTAL FEES $ ________

PAYMENT INFORMATION:

☐ Enclosed is payment by CHECK payable to the American Association for the Treatment of Opioid Dependence, Inc.

To assure prompt processing of your registration, please be sure to remit your check in U.S. dollars and issued by a U.S. correspondent bank. Please check with your local bank before processing payment. Each registrant is responsible for any and all bank charges. A $50.00 processing fee will be charged for checks returned unpaid.

☐ I wish to pay my fees by CREDIT CARD

Please note this charge will appear on your statement as “AATOD Conference Registration”

Visa ☐ MasterCard ☐ American Express

Please provide card number and expiration date below.

Cardholder’s Signature ________________________________________________________________________

Total fees to be charged $ ______________

Registrations paid by credit card may be faxed to 856-423-3420. Please keep a copy of your fax confirmation for your record. If faxing, DO NOT mail the original form; doing so may result in duplicate charges to your credit card! AATOD reserves the right to charge the correct amount if different from the total above.

AATOD does not accept purchase orders as a form of payment.

CANCELLATION POLICY
If you must cancel your registration, the American Association for the Treatment of Opioid Dependence, Inc. Registration Department must receive all requests in writing no later than March 30, 2012. All fees paid will be returned less a $50.00 processing fee. There will be no refunds after the March 30th deadline.

REPLACEMENT POLICY
Replacements will only be processed when requests are received in writing prior to March 30, 2012. There will be NO replacements after that date.

Participation in this conference assumes knowledge and authorization of audio and/or video recording of portions of this conference.

Registration will be confirmed in writing within two weeks of receipt of payment. If you do not receive confirmation by that time, please call 856-423-3091.

Credit Card Information

ACCOUNT NUMBER ________ ________ ________ ________ ________ ________ ________ ________

EXPIRATION DATE (mm/yy) ________ ________
American Association for the Treatment of Opioid Dependence, Inc.
19 Mantua Road
Mt. Royal, NJ 08061
www.aatod.org

Recovery for Patients, Families and Communities